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ABSTRACT
Objectives. The objective of this study was to assess the
impact of unresected primary tumor, as well as extrahep-
atic metastasis, on the long-term prognosis of patients
undergoing hepatic resection for non-functional neuroen-
docrine liver metastasis (NF-NELM).
Methods. Patients who underwent hepatic resection for
NF-NELM were identified from a multi-institutional data-
base. Data on clinical and pathological details, as well as
the long-term overall survival (OS) were obtained and
compared. Propensity score matching was performed to
generate matched pairs of patients.
Results. Among the 332 patients with NF-NELM, 281
(84.6%) underwent primary tumor resection, while 51
(15.4%) did not. Patients who underwent primary resection
were more likely to have a pancreatic primary and meta-
chronous NELM. The long-term OS of patients who did
and did not have the primary neuroendocrine tumor (NET)
resected was comparable on both unmatched (10-year
survival rate 66.8% vs. 54.0%, p = 0.192) and matched
(10-year survival rate 75.7% vs. 60.4%, p = 0.271) analy-
ses. In contrast, patients with NF-NELM and extrahepatic
metastasis had a worse OS following resection compared
with patients who had intrahepatic-only metastasis on
unmatched (10-year survival rate 37.5% vs. 69.3%,
p = 0.002) and matched (10-year survival rate 37.5% vs.
86.3%, p = 0.011) analyses. On multivariable analysis,
while resection of the primary NET was not associated
with OS (hazard ratio [HR] 0.7, 95% confidence interval
[CI] 0.4–1.2, p = 0.195), the presence of extrahepatic
metastasis was independently associated with long-term
risk of death (HR 3.9, 95% CI 1.7–9.2, p = 0.002).
Conclusions. While surgery should be considered for
patients with NF-NELM who have an unresectable primary
tumor, operative resection of NF-NELM may not be as
beneficial in patients with extrahepatic disease.
Gastroenteropancreatic neuroendocrine tumors (GEP-
NETs) are a heterogeneous group of rare tumors arising
mainly from the pancreas and gastrointestinal tract.1 While
some GEP-NETs may have an indolent course, the liver is
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a common metastatic site for GEP-NETs. In fact, up to
60–90% of patients may develop synchronous or meta-
chronous neuroendocrine liver metastasis (NELM) during
the course of their disease.
Surgical resection is the main curative treatment option
for patients with NELM.2 Treatment goals for NELM often
include both prolongation of survival and alleviation of
tumor-related symptoms, which can include debilitating
hormonal symptoms and mechanical symptoms.3 While a
subset of patients have functional tumors, a recent study of
9281 patients from the National Cancer Data Base with
pancreatic NETs demonstrated that over 75% of NETs
were non-functional.4 Due to the lack of early symptoms,
non-functional neuroendocrine tumors with liver metastasis
(NF-NELM) are often discovered late, which can result in a
higher incidence of the primary lesion being unre-
sectable and/or the presence of extrahepatic metastasis.4–6
NF-NETs are also more likely to be malignant and are
often associated with worse outcomes versus functional
NETs.6–9
Traditionally, the presence of unresectable primary
disease and/or extrahepatic metastatic disease was consid-
ered advanced NELM.10 While some investigators have
recommended against resection of NELM in the setting of
advanced disease,11 other data have supported surgical
debulking as a reasonable treatment of NELM that has
yielded improved long-term survival.12 As most patients
with NELM die of liver failure due to intrahepatic tumor
progression rather than the primary tumor or extrahepatic
disease, liver resection may have a role, even in the setting
of advanced disease.12,13 However, whether the presence of
an unresectable primary tumor and/or extrahepatic meta-
static disease should be considered a contraindication to
liver resection for NF-NELM remains debated. As such,
the objective of the current study was to define the impact
of an unresected primary tumor and/or extrahepatic meta-
static disease on the long-term prognosis of patients
undergoing hepatic resection for NF-NELM.
METHODS
Study Cohort
A total of 548 patients who underwent liver-directed
therapy for NELM from January 1980 to December 2015
were identified from nine international institutions. The
Institutional Review Board of all participating institutions
approved the study. The diagnoses of all NELM patients
were confirmed histologically. Patients with hormonally
functional NETs (n = 201), receipt of liver ablation only
(n = 11), and patients who died within 30 days after sur-
gery (n = 4) were excluded.
Data Collection and Follow-Up
Data on clinical, operative, and pathological details
were collected for each patient at each institution in a
standardized database pertaining to both the primary tumor
and liver metastases. Extrahepatic metastatic disease was
determined by imaging studies, e.g. computed tomography
(CT) scan, octreoscan, positron emission tomography
(PET)-CT, etc., and/or biopsy before surgery among the
different centers. Grade of tumor differentiation was clas-
sified as well (G0), moderate (G1), or poor (G3) according
to the 2010 WHO grading system.14 An R0 resection was
defined as the absence of macroscopic or microscopic
disease at the surgical margin, while an R1 resection was
defined as the microscopic presence of tumor and R2 was
classified as macroscopic presence of tumor.15
Statistical Analysis
Continuous variables were expressed as medians with
interquartile ranges (IQRs), while categorical variables
were reported as totals and frequencies. Univariable com-
parisons were assessed by using the Mann–Whitney U test,
Chi square test, or Fisher exact test, as appropriate. Sur-
vival was evaluated using Kaplan–Meier curves and
median values were compared using the log-rank tests. The
impact of various clinicopathological factors on overall
survival (OS) was assessed using a Cox proportional haz-
ards model and expressed as hazard ratio (HR) and 95%
confidence interval (CI). Factors with a p value\ 0.05 by
univariate analysis were included in the multivariate
analysis. Propensity score matching (PSM) was used to
adjust for differences in baseline characteristics between
groups. In all analyses, a p value\ 0.05 (two-tailed) was
considered statistically significant. Statistical analyses were
performed using SPSS 22.0 (IBM Corporation, Armonk,
NY, USA).
RESULTS
Demographic and Clinicopathological Characteristics
Among the 548 patients diagnosed with GEP-NETs, a
total of 332 (60.6%) patients who underwent hepatectomy
for NF-NELM were included in the analytic cohort
(Table 1). Median patient age was 58 years (IQR 49–67)
and nearly half of patients were female (n = 151, 45.5%).
Among all patients, 187 (56.3%) presented with non-
specific clinical symptoms, including abdominal cramping.
Primary tumor site included the pancreas (n = 149, 44.9%),
gastrointestinal tract (n = 129, 38.8%), tracheobronchial
and lung (n = 14, 4.2%), and unknown location (n = 40,
12%). Liver metastases were synchronous in 217 (65.4%)
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patients and metachronous in 115 (34.6%) patients. Bilat-
eral liver disease was present in the majority of patients
(n = 181, 54.5%) and most patients had an esti-
mated C 50% liver involvement (n = 440, 79.4%).
Extrahepatic metastatic disease was noted in 37 (11.1%)
patients at the time of liver surgery. Most patients
(n = 283, 85.2%) did not receive any additional treatment
before hepatectomy, while 22 (6.6%) and 27 (8.1%)
patients had received octreotide or chemotherapy, respec-
tively. Most patients (n = 205, 61.7%) underwent a
parenchymal-sparing resection. During the operation,
tumor ablation was concomitantly performed in 76 (22.9%)
patients. On final pathology, 291 (87.7%) patients had a
curative-intent resection (R0/R1), while 41 (12.3%)
patients had a macroscopically positive (R2) surgical
margin. The majority of patients (n = 203, 61.1%) did not
receive any adjuvant treatment, whereas 129 (38.9%)
patients received postoperative octreotide or
chemotherapy.
Overall Survival (OS): Primary Resected Versus
Unresected Non-functional Neuroendocrine Liver
Metastasis (NF-NELM)
Among the 332 patients with NF-NELM, the primary
tumor was resected in 281 (84.6%) patients; 51 (15.4%)
patients had an unresected primary tumor at the time of
liver surgery for NELM (Fig. 1). The 1-, 3-, 5-, and 10-year
survival of the entire cohort was 97.4, 89.5, 82.2, and
65.1%, respectively. Patients who had a resected primary
TABLE 1 Clinicopathological characteristics of patients who underwent hepatic resection for non-functional neuroendocrine liver metastasis
All patients (n = 332) Primary resected (n = 281) Primary unresected (n = 51) p Value
Age, years (IQR) 58 (49–67) 58 (49–67) 48 (42–67) 0.863
Sex, male/female 181 (54.5)/151 (45.5) 160 (56.9)/121 (43.1) 21 (41.2)/30 (58.8) 0.038
Symptomatic 187 (56.3) 164 (58.4) 23 (45.1) 0.079
Primary tumor location \ 0.001
Non-pancreatic 183 (55.1) 137 (48.8) 46 (90.2)
Pancreatic 149 (44.9) 144 (51.2) 5 (9.8)
Synchronous liver metastasis 217 (65.4) 176 (62.6) 41 (80.4) 0.014
Bilateral liver metastasis 181 (54.5) 157 (55.9) 24 (47.1) 0.245
Estimated liver involvement 0.662
\ 50% 58 (17.5) 48 (17.1) 10 (19.6)
C 50% 274 (82.5) 233 (82.9) 41 (80.4)
Tumor grade 0.015
Well-differentiated 129 (57.1) 122 (59.5) 7 (33.3)
Moderately differentiated 53 (23.5) 48 (23.4) 5 (23.8)
Poorly differentiated 44 (19.5) 35 (17.1) 9 (42.9)
NA/missing 106 76 30
Extrahepatic disease 37 (11.1) 30 (10.7) 7 (13.7) 0.524
Preoperative treatment 0.218
Octreotide 22 (6.6) 20 (7.1) 2 (3.9)
Chemotherapy 27 (8.1) 20 (7.1) 7 (13.7)
None 283 (85.2) 241 (85.8) 42 (82.4)
Intraoperative ablation 76 (22.9) 69 (24.6) 7 (13.7) 0.090
Type of hepatectomy 0.019
Parenchymal-sparing resection 205 (61.7) 181 (64.4) 24 (47.1)
Major resection 127 (38.3) 100 (35.6) 27 (52.9)
Margin 0.030
R0/R1 291 (87.7) 251 (89.3) 40 (78.4)
R2 41 (12.3) 30 (10.7) 11 (21.6)
Adjuvant therapy 129 (38.9) 114 (40.6) 15 (29.4) 0.133
Data are expressed as n (%) unless otherwise specified
IQR interquartile range, NA not available
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tumor were more likely to be male (56.9% vs. 41.2%,
p = 0.038) and have a pancreatic NET (51.2% vs. 9.8%,
p\ 0.001) versus patients who had a primary NET that
was not resected (Table 1). More patients with an unre-
sected primary tumor presented with a synchronous liver
metastasis compared with patients who had the primary
NET resected (80.4% vs. 62.6%, p = 0.014). Although
tumor burden was not different among patients with a
resected versus unresected primary tumor (C 50% liver
involvement, 82.9% vs. 80.4%, p = 0.662), patients who
had the primary tumor resected were more likely to
undergo parenchymal-sparing hepatic resection (64.4% vs.
47.1%, p = 0.019) and had a higher incidence of curative-
intent resection (R0/R1, 89.3% vs. 78.4%, p = 0.030)
versus patients with an unresected primary tumor
(Table 1). Patients with a primary resected tumor were
more likely to have a well-differentiated tumor (59.5%),
while patients with a primary unresected tumor were more
likely to have a poorly differentiated tumor (42.9%,
p = 0.015). Lymph node metastasis was present in 105
(37.4%) patients.
Patients who underwent primary NET resection had a
comparable long-term OS versus patients who had an
unresected NET primary (10-year survival rate, primary
resected 66.8% vs. unresected 54.0%, p = 0.192) [Fig. 2a].
The propensity-matched cohort included 90 patients who
did or did not have the primary NET resected (Electronic
Supplementary Table 1). In the matched cohort, OS was
equivalent among patients who had the primary NET
resected versus patients who had an unresected primary
NET (10-year survival rate, primary resected 75.7% vs.
unresected 60.4%, p = 0.271) [Fig. 2b]. Of note, no
differences in OS were identified among patients under-
going hepatic resection for NF-NELM among the different
eras (1980–2000 vs. 2001–2010 vs. after 2011, p = 0.396)
[Electronic Supplementary Fig. 1].
OS: Presence of Extrahepatic Metastatic Disease
Versus Intrahepatic-Only Metastasis
At the time of NF-NELM resection, extrahepatic meta-
static disease was noted in 37 (11.1%) patients (Fig. 1).
Extrahepatic sites included the lungs (n = 11), peritoneum
(n = 19), bone (n = 7), and other sites (n = 12); 9 patients
had multiple sites of extrahepatic metastases. Compared
with patients who had intrahepatic-only disease, patients
with NF-NELM plus extrahepatic metastasis were more
likely to have a pancreatic primary tumor (47.5% vs.
24.3%, p = 0.008) [Electronic Supplementary Table 2].
Patients with extrahepatic metastatic disease had a worse
OS versus patients with intrahepatic-only metastasis (10-
year survival rate, 69.3% vs. 37.5%, p = 0.002) [Fig. 3a].
After 1:2 PSM, the analytic cohort included 95 patients
who had comparable demographic and clinicopathologic
characteristics (Electronic Supplementary Table 2). In the
matched cohort, the presence of extrahepatic metastatic
disease remained associated with worse long-term outcome
(10-year survival, extrahepatic metastatic disease 36.3%
vs. intrahepatic-only disease 77.9%, p = 0.019) [Fig. 3b].
Risk Factors Associated with OS of NF-NELM
On univariate analysis, symptomatic, pancreatic primary
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FIG. 1 Patient inclusion and study scenario. NELM neuroendocrine liver metastasis, POD postoperative day
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grade, and extrahepatic metastatic disease were each
associated with worse long-term survival among patients
with NF-NELM (Table 2). Of note, resection of the pri-
mary NET was not associated with OS (HR 0.7, 95% CI
0.4–1.2, p = 0.195). On multivariable analysis, after taking
into account all potential confounding factors, the presence
of extrahepatic metastatic disease (HR 3.9, 95% CI
1.7–9.2, p = 0.002) remained independently associated
with worse outcome among patients with NF-NELM.
DISCUSSION
With improvements in abdominal imaging, the inci-
dence of NF-NETs has increased to 50–75% of all GEP-
NETs.16 In fact, over half of NF-NET patients are
asymptomatic and have disease sporadically discovered on
imaging for an unrelated problem.14,17,18 Due to occult
progression and delayed diagnosis, more NF-NET patients
may present with an unresectable primary tumor and
extrahepatic metastasis than patients with functional
NETs.14,17,18 In turn, the presence of unresectable primary
NETs and/or extrahepatic metastasis are still considered a
contraindication to surgery by many clinicians.11,19 How-
ever, aggressive onco-surgery has been increasingly
advocated, even in the presence of advanced metastatic
disease.20,21 The current study was important as it specif-
ically defined the outcomes of patients with advanced NF-
NELM who had unresected primary NETs, as well as
extrahepatic metastasis using a large, international, multi-
institutional database. Of note, long-term survival was
comparable among patients who had the primary NET
resected versus patients who had an unresectable primary
NET left in situ. Comparable long-term OS among patients
who did and did not have the primary NET resected was
noted on both unadjusted (10-year survival rate 66.8% vs.
54.0%, p = 0.192) and adjusted (10-year survival rate
75.7% vs. 60.4%, p = 0.271) analyses. In contrast, the
presence of extrahepatic metastatic disease was strongly
associated with a worse OS compared with intrahepatic-
only disease as patients who had extrahepatic metastatic
disease were noted to have a 2.5-fold higher risk of death
long-term.
The beneficial role of resecting the primary NET has
been a topic of debate. Givi et al. reported on 84 patients
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FIG. 2 Overall survival after curative-intent surgery for primary
resected and unresected non-functional neuroendocrine liver












































FIG. 3 Overall survival of non-functional neuroendocrine liver
metastasis patients with or without extrahepatic metastatic disease
before (a) and after (b) propensity score matching
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noted that primary tumor resection was associated with
improved survival.22 However, all patients in this study
received non-surgical treatment for NELM.22 Whether
there is a role for surgical resection of NF-NELM in the
setting of an unresected primary NET remains largely
unknown. Importantly, data from the current study
demonstrated comparable long-term survival among
patients who did and did not have the primary NET
resected. In fact, the presence of an unresected primary
NET was not a risk factor for OS among patients under-
going resection of NF-NELM. As such, hepatic resection of
NF-NELM should be strongly considered, even in the
setting of an unresectable primary NET tumor.
According to the European Neuroendocrine Tumor
(ENET) system, as well as other investigators, the presence
of extrahepatic metastatic disease is a strong negative
prognostic factor and should be considered a relative
contraindication to surgery among patients with
NELM.8,9,23,24 In the current study, patients with extra-
hepatic metastasis who underwent resection of NELM had
a more than twofold increased risk of death long-term.
Interestingly, the 10-year survival of patients with extra-
hepatic NET disease who underwent resection of NELM
was still almost 40%. Whether patients with non-functional
NET who have extrahepatic metastatic disease and exten-
sive NELM benefit from surgery is controversial. Mayo
et al. reported on patients with NELM who were treated
with surgery versus intra-arterial therapy (IAT) and noted
an overall improved survival with surgery23 However,
among patients who had an NF-NET and large ([ 50%)
liver involvement, there was no difference in survival
among patients who underwent resection versus IAT.23
Similarly, Kennedy et al. reported the benefit of Y-90
microsphere therapy in the treatment of patients with
advanced NETs.25 Overall, the presence of extrahepatic
metastatic disease has been reported to have a varied effect
on long-term prognosis relative to the extent of liver dis-
ease.12,13,26,27 In one study using the Surveillance,
Epidemiology, and End Results (SEER) database, Franko
et al. examined patients with non-functional PNETs and
reported that while distant metastasis was a negative
prognostic marker, surgical resection improved the long-
TABLE 2 Risk factors
associated with overall survival
rate of non-functional
neuroendocrine liver metastasis
Univariate analysis Multivariate analysis
HR (95% CI) p Value HR (95% CI) p Value
Age, B 60/[ 60 years 0.9 (0.6–1.4) 0.613
Sex, male/female 1.5 (0.9–2.4) 0.089
Symptomatic 1.7 (1.0–2.7) 0.030 1.6 (0.8–2.9) 0.158
Primary tumor location 0.005 0.002
Non-pancreatic Ref. Ref.
Pancreatic 1.9 (1.2–3.1) 2.8 (1.4–5.4)
Primary tumor resected 0.7 (0.4–1.2) 0.195
Synchronous liver metastasis 2.5 (1.5–4.2) \ 0.001 2.1 (1.0–4.1) 0.037
Bilateral liver metastasis 0.9 (0.6–1.5) 0.758
Estimated liver involvement,\ 50%/C 50% 0.9 (0.5–1.6) 0.727
Tumor grade
Well-differentiated Ref. Ref.
Moderately differentiated 4.0 (2.0–8.0) \ 0.001 3.0 (1.5–6.1) 0.003
Poorly differentiated 4.1 (2.0–8.4) \ 0.001 2.2 (0.9–5.2) 0.067
Extrahepatic disease 2.4 (1.3–4.1) 0.002 3.9 (1.7–9.2) 0.002
Preoperative treatment
None Ref.
Octreotide 0.8 (0.2–2.4) 0.650
Chemotherapy 1.7 (0.8–3.6) 0.197
Intraoperative ablation 1.2 (0.7–2.0) 0.516
Types of hepatectomy 0.088
Parenchymal-sparing resection Ref.
Major resection 0.7 (0.4–1.1)
Margin \ 0.001 0.027
R0/R1 Ref. Ref.
R2 3.9 (2.2–6.9) 2.5 (1.1–5.6)
HR hazard ratio, CI confidence interval, Ref. reference
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term outcome of patients with distal metastasis versus non-
surgical treatments.6 However, given the limitations of the
SEER dataset, this study had no clear classification of what
constituted a ‘true’ distant metastasis.6 Collectively, the
data would suggest that hepatic resection of NF-NELM
may be reasonable in the presence of low-volume extra-
hepatic disease.8,28 However, given the higher risk of poor
long-term outcomes defined in the current study, patients
with a large burden of intra- and extrahepatic disease may
not derive a strong benefit from surgery, and less invasive
therapeutic approaches such as IAT should be considered.
The current study had several limitations. The multi-in-
stitutional nature of the cohort allowed for an increased
sample size to examine a relatively rare disease, yet selec-
tion criteria for surgery among different centers may have
been inconsistent, and the heterogeneity of the patient
population may have allowed for certain biases. In addition,
only patients who underwent hepatic resection for NF-
NELM were included in the current database; therefore,
‘control’ patients who were untreated or received non-sur-
gical treatment were not available for comparison purposes.
As such, the survival benefit of resection versus nonsurgical
treatments among patients with presence of primary unre-
sected or extrahepatic metastatic disease might be limited in
the current study, which needs to be further evaluated.
CONCLUSIONS
At the time of surgical treatment for NF-NELM,
approximately 1 of 7 and 1 of 10 patients presented with an
unresectable primary tumor and/or extrahepatic disease,
respectively. Patients with primary unresected NET had a
comparable survival versus patients who had the primary
NET resected. In contrast, survival among patients with
extrahepatic metastatic disease was worse versus patients
who had intrahepatic-only disease. While surgery should be
considered for patients with NF-NELM who have an unre-
sectable primary tumor, operative resection of NF-NELM
may not be as beneficial in patients with extrahepatic disease.
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